Does AXA Health Insurance Cover Weight Loss Injections?

What NICE guidance says, and why insurers often look the other way

NICE has formally recommended tirzepatide (Mounjaro) for weight management in England under technology appraisal TA1026, published in December 2024. Semaglutide (Wegovy) received its own NICE recommendation under TA875 back in March 2023. Both appraisals drew on substantial clinical trial evidence: the SURMOUNT-1 trial reported around 20–21% average body weight reduction over 72 weeks for tirzepatide at 15mg, and STEP 1 found roughly 15% average reduction for semaglutide 2.4mg over 68 weeks. These are meaningful, well-documented outcomes, and they form the basis of the NHS rollout.

Private insurers, however, are not bound by NICE recommendations. AXA Health, like most UK private medical insurance providers, tends to draw a distinction between acute illness (typically covered) and chronic condition management that includes lifestyle factors. Weight management usually sits in the latter camp. Some policies have special clauses for obesity-related comorbidities (type 2 diabetes treatment or sleep apnoea management, for instance) but that rarely extends to funding the weight loss injection itself. A common misconception is that having a NICE-recommended medicine automatically means your insurer will fund it; in practice, NICE guidance directs NHS commissioning, not private insurance contracts.

The practical step is to request the exact benefit schedule from AXA in writing and ask specifically whether prescription medicine costs for a NICE-approved obesity treatment are included under any supplementary benefit.

NHS access to weight loss injections, and where private prescription fits in

For those who don't have private cover, the NHS route exists but is currently phased. Under the tirzepatide rollout, the first cohort (from June 2025) requires a BMI of 40 or above alongside four or more of five qualifying conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort (BMI 35–39.9 with four or more of those conditions) became eligible from late June 2026. NHS access to Wegovy is via specialist weight management services, where waiting times can be considerable.

People who meet the licensed eligibility criteria but fall outside the current NHS cohorts, or who simply cannot wait, often turn to private prescription. The NHS England guidance on weight management injections sets out both the NHS criteria and the clinical context clearly. Understanding where you sit relative to those thresholds is a sensible first step before deciding how to proceed. If you want to understand the qualifications that apply to private treatment, the eligibility criteria for weight loss injections are covered in detail elsewhere on this site.

Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the clinical adjustment is 2.5 kg/m² in each case, meaning a BMI of 27.5 rather than 30, for example, may still qualify.

What a private prescription actually costs, and what to look for

If insurance cover isn't available, private prescription is a self-funded route, and the cost landscape shifted significantly when Eli Lilly revised Mounjaro's UK list price from 1 September 2025. Reported private market prices since then range roughly £149–£375 per month depending on dose and provider, reflecting the substantial increase at higher doses. These figures are widely reported and worth knowing, though they vary. What headline prices sometimes omit is whether the consultation, prescription fee, and clinical aftercare are included, or billed separately.

For context on how those costs break down, the weight-loss treatments page explains what a clinically supervised private route involves. Reputable providers include all of those elements in a single price; those that don't can make comparison misleading. Separately, the evidence on whether weight loss injections work is worth reviewing before making any financial decision, because understanding the trial data helps set realistic expectations alongside cost.

How to access weight loss injections safely if you're funding it yourself

Mounjaro and Wegovy are prescription-only medicines under UK law. That means no legitimate seller can supply them without a prescriber assessing your suitability first, and any supplier offering them without that step is acting illegally. The MHRA has warned repeatedly about counterfeit weight loss pens sold online, including fake products that have contained insulin. Verifying any online pharmacy on the GPhC register before placing an order takes less than a minute and is the clearest way to confirm legitimacy.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician, not a decision tree. Orders placed before 12pm on working days are dispatched the same day once clinically approved, and arrive the next working day via DPD in plain packaging. The standards that make a weight loss injection service reputable include more than speed: ID verification, live weight checks, GP notification and clinical review before every repeat order all matter. If you have questions about how the weight loss injection works, the FAQs cover the most common ones, and our team is reachable via the contact page if something specific isn't answered there. If you're also trying to figure out who does weight loss injections near you, that information is available on this site too.